

# San Francisco

## Spring Group Meeting

# SPECIALS

## Melanoma Committee

# Melanoma Committee

## Leadership

Chair: ..... Sapna P. Patel, MD  
 Vice-Chair: ..... Roger S. Lo, MD, PhD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Michael Wu, PhD  
 ..... James Moon, MS  
 ..... Allison Hayes, BS

## Scientific Leadership

Translational Medicine: ..... William E. Carson, III, MD  
 Radiation Oncology: ..... TBD  
 Surgery: ..... John Robert Hyngstrom, MD  
 Dermatology: ..... TBD  
 Imaging: ..... TBD  
 Medical Oncology: ..... TBD  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Nikhil I. Khushalani, MD  
 Early Therapeutics: ..... TBD  
 SWOG's ECOG Liaisons: ..... Thach-Giao Truong, MD  
 ECOG's SWOG Liaisons: ..... David H. Lawson, MD  
 ..... Michael Lowe, MD  
 Digital Engagement: ..... Zeynep Eroglu, MD

## Designates

Prevention: ..... Sancy Leachman, MD, PhD  
 Data Coordinator: ..... Cassie Villasin, BA  
 ..... Michele Counts, BS, CCRP  
 ..... Tonya Johnson, BA  
 Oncology Research Professionals:  
     CRA: ..... Kathryn Allen, BA, CCRP  
     Nurse: ..... TBD  
 Patient Advocate: ..... TBD  
 Pharmaceutical Science: ..... Sun "Coco" Yang, PharmD, PhD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Saturday, May 3, 2025 12:30 p.m. - 2:30 p.m.  
 Room: Grand Ballroom B (Street Level)

## Keynote Speaker

The Sex-Specific Shield: Chromosomes, Hormones, and CD8 T Cell Immunity in Cancer - Zihai Li, MD, PhD, Klotz Memorial Chair in Cancer Research, Professor and Founding Director, Pelotonia Institute for Immuno-Oncology, Deputy Director for Translational Research, The Ohio State University Comprehensive Cancer Center

## Presentations

Artificial intelligence-powered pathology biomarkers for prognosis and prediction of treatment response in stage III and IV cutaneous melanoma, Anirudh Joshi, Valar Labs

Hope Foundation Impact Award Grant Update, Roi Weiser, MD, Assistant Professor, Department of Surgical Oncology, MD Anderson Cancer Center

## Active Studies

**S2015**, "Melanoma Margins Trial (MeMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

**CTSU/EA6192**, "The BMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

**A091903**, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023

## Studies in Development

**S2431**, "Randomized, open-label, phase III study of anti-PD-1, anti-CTLA-4, and anti-LAG-3 antibodies in patients with previously untreated unresectable or metastatic melanoma". Dr. Chandra

# Melanoma Committee

## Closed Studies

**CTSU/EA6174**, “STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial.” SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

**S2000**, “A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases.” Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

**S1801**, “A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma.” Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

**S1512**, “A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM).” Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

**S1607**, “A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

**S1616**, “A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

**S1404**, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

**CTSU/EA6134**, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

**CTSU/EA6183**, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPh Activated: 02/18/2020. Closed: 09/23/2022.

## Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

### Published/Accepted Manuscripts

**S0826** Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Cancer. Jan 1;131(1):e35587, 2025. <https://pubmed.ncbi.nlm.nih.gov/39342463/>

### Submitted Manuscripts

**S1512** Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A).. Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Bartosz Chmielowski, Nikhil I. Khushalani, Joseph Markowitz, Marcus Monroe, Carlo Contreras, Egmidio Medina, Gonzalez C, Baselga-Carretero I, Garcilazo I, Vega-Crespo A, Chen J, Al-Deen N, Patel S, Grossmann K, Sondak V, Sharon E, Moon J, Wu M, Ribas A. Submitted.

**S1512** High response rate with single agent anti-PD-1 therapy in patients with unresectable desmoplastic melanoma (SWOG S1512 cohort B). Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, Sosman J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Khushalani N, Markowitz J, Negrea G, Kasbari S, Doolittle G, Swami U, Roberts T, Medina E, Baselga-Carretero I, Gonzalez C, Garcilazo I, Vega-Crespo A, JChen J, Al-Deen N, Patel S, Sharon E, Moon J, Wu M, Ribas A. Submitted.

**S1801** Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. Submitted.



# Melanoma Committee

**Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study**

|   | S2000     | S2015      | A091903  | EA6141    | EA6174    | EA6192   | EA6194   |
|---|-----------|------------|----------|-----------|-----------|----------|----------|
| Banner MD Anderson Cancer Center                                | -         | 25         | -        | -         | -         | -        | -        |
| Banner University Medical Center - Tucson                       | -         | -          | -        | -         | 3         | -        | 1        |
| CWRU Case Comprehensive Cancer Center LAPS                      | -         | -          | -        | -         | 16        | -        | -        |
| Cancer Research Consortium of West Michigan NCORP               | -         | 90         | -        | -         | -         | -        | -        |
| Cancer Research for the Ozarks NCORP                            | 1         | -          | -        | 1         | -         | -        | -        |
| Carle Cancer Center NCI Comm Oncology Research Program          | 1         | -          | -        | -         | -         | -        | -        |
| Cedars-Sinai Medical Center                                     | -         | 23         | -        | -         | -         | -        | -        |
| City of Hope Comprehensive Cancer Center                        | -         | -          | -        | 3         | -         | -        | -        |
| Columbia University Minority Underserved NCORP                  | -         | 6          | -        | -         | -         | -        | -        |
| Dayton NCI Comm Oncology Research Program                       | 1         | -          | -        | 2         | -         | -        | -        |
| Duke University - Duke Cancer Institute LAPS                    | -         | 10         | -        | -         | -         | -        | -        |
| Fred Hutchinson Cancer Research Center LAPS                     | -         | -          | -        | -         | 1         | -        | -        |
| Froedtert & the Medical College of Wisconsin LAPS               | -         | 10         | -        | -         | -         | -        | -        |
| Georgia NCI Comm Oncology Research Program                      | -         | 10         | -        | -         | -         | -        | -        |
| Intermountain Medical Center                                    | -         | 30         | -        | -         | -         | -        | -        |
| Kaiser Permanente NCI Comm Oncology Research Program            | -         | 3          | -        | 29        | -         | -        | -        |
| Medical University of South Carolina Minority Underserved NCORP | -         | 15         | -        | -         | -         | -        | -        |
| Moffitt Cancer Center   | 20        | 51         | -        | -         | -         | -        | -        |
| Nevada Cancer Research Foundation NCORP                         | -         | -          | -        | -         | 1         | -        | -        |
| New Mexico Minority Underserved NCORP                           | -         | 3          | -        | -         | -         | -        | -        |
| Northwell Health NCORP  | -         | 7          | -        | -         | -         | -        | -        |
| Northwestern University LAPS                                    | -         | 33         | -        | 1         | 1         | 5        | -        |
| Ohio State University Comprehensive Cancer Center LAPS          | 3         | 31         | -        | -         | 3         | 3        | -        |
| Saint Joseph Hospital - Cancer Centers of Colorado              | -         | -          | -        | -         | 1         | -        | -        |
| Sutter Cancer Research Consortium                               | -         | -          | -        | 7         | 1         | -        | -        |
| UC Irvine Health/Chao Family Comprehensive Cancer Center        | -         | 13         | -        | 4         | 8         | -        | 3        |
| UPMC Hillman Cancer Center LAPS                                 | 1         | -          | -        | -         | -         | -        | -        |
| USC Norris Comprehensive Cancer Center LAPS                     | -         | 2          | 1        | -         | 3         | -        | -        |
| University of Arkansas for Medical Sciences                     | -         | 6          | -        | -         | -         | 1        | -        |
| University of Cincinnati Cancer Center-UC Medical Center        | -         | -          | -        | 2         | 4         | -        | -        |
| University of Kansas Cancer Center - MCA Rural MU NCORP         | -         | 45         | -        | 2         | 1         | -        | -        |
| University of Kentucky/Markey Cancer Center                     | -         | 7          | -        | -         | -         | -        | -        |
| University of Michigan Comprehensive Cancer Center LAPS         | 2         | 17         | -        | -         | -         | -        | -        |
| University of Nebraska Medical Center                           | -         | 2          | -        | -         | -         | -        | -        |
| University of Oklahoma Health Sciences Center LAPS              | -         | 1          | -        | -         | -         | -        | -        |
| University of Rochester LAPS                                    | -         | 6          | -        | 8         | 1         | -        | -        |
| University of Texas Health Science Center at San Antonio        | -         | 3          | -        | 1         | -         | -        | -        |
| University of Texas MD Anderson Cancer Center LAPS              | -         | 18         | -        | -         | -         | -        | -        |
| University of Utah - Huntsman Cancer Institute LAPS             | -         | 28         | -        | -         | 8         | -        | -        |
| Western States Cancer Research NCORP                            | -         | -          | -        | 1         | -         | -        | -        |
| Wisconsin NCI Comm Oncology Research Program                    | -         | 13         | -        | -         | -         | -        | -        |
| Yale University - Yale Cancer Center LAPS                       | -         | 23         | -        | 8         | 1         | -        | -        |
| ALLIANCE  | 1         | 89         | -        | -         | -         | -        | -        |
| ECOG-ACRIN  | 6         | 188        | -        | -         | -         | -        | -        |
| NRG   | 1         | 83         | -        | -         | -         | -        | -        |
| <b>Total</b>  | <b>37</b> | <b>891</b> | <b>1</b> | <b>69</b> | <b>53</b> | <b>9</b> | <b>4</b> |

